Do you want to read an article? Please log in or register.
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study
J Crohns Colitis
Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S
doi: 10.1093/ecco-jcc/jjaf052
Inflammatory Bowel Disease
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
Lancet Gastroenterol Hepatol
Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group
doi: 10.1016/S2468-1253(25)00291-2
Inflammatory Bowel Disease
Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis
Inflamm Bowel Dis
Nishida Y, Hosomi S, Fujimoto K, Kobayashi Y, Nakata R, Maruyama H, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Fujiwara Y
doi: 10.1093/ibd/izaf302
Inflammatory Bowel Disease
Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study
Clin Gastroenterol Hepatol
Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, Amiot A, Vuitton L, Treton X, Caillo L, Pereira B, Fumery M
doi: 10.1016/j.cgh.2025.07.044
Further Publications
A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch
Am J Gastroenterol
Barnes EL, Raffals L, Qazi T, Deepak P, Chang S, Beniwal-Patel P, Higgins PD, Cross RK, Barr JI, Anderson C, Long MD, Herfarth HH, Dubinsky M, Kappelman MD, Kayal M
doi: 10.14309/ajg.0000000000003608
Inflammatory Bowel Disease
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Inflamm Bowel Dis
Yarur A, Irving P, Siegmund B, Dubinsky MC, Ananthakrishnan AN, Regueiro M, Ungaro RC, Ritter T, Nakase H, Liu Z, Mehra D, Osterman MT, Jain A, Rubin DT, Hibi T
doi: 10.1093/ibd/izaf195
RECOMMENDED
Inflammatory Bowel Disease
Efficacy of 5-Aminosalicylic Acid Continuation versus Discontinuation in Patients with Ulcerative Colitis Escalated to Advanced Therapy: A Systematic Review and Meta-Analysis of Adjusted Effect Estimates
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Sul HH, Gewehr DM, Kang H, Junior OR, Ungaro RC, Bernstein CN
doi: 10.1093/ecco-jcc/jjaf202
Gastrointestinal Cancer
Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma
J Natl Compr Canc Netw
Verhoeven RHA, Kuijper SC, Lordick F, Slingerland M, Qin A, van Laarhoven HWM
doi: 10.6004/jnccn.2025.7058
Inflammatory Bowel Disease
Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis
Inflamm Bowel Dis
Desai A, Habib H, Khataniar H, Farraye FA, Sehgal P, Barnes EL, Kochhar GS, Hashash JG
doi: 10.1093/ibd/izaf301